Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata

Y Renert‐Yuval, AB Pavel, E Del Duca, P Facheris… - Allergy, 2023 - Wiley Online Library
Background The mechanisms driving alopecia areata (AA) are still unclear, hindering
development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides …
被引用次数：27 相关文章

Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata

Y Renert-Yuval, AB Pavel, E Del Duca, P Facheris… - 2023 - pubmed.ncbi.nlm.nih.gov
Background The mechanisms driving alopecia areata (AA) are still unclear, hindering
development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides …

Scalp Biomarkers During Dupilumab Treatment Support Th2 Pathway Pathogenicity in Alopecia Areata.

Y Renert-Yuval, AB Pavel, E Del Duca, P Facheris… - Allergy, 2022 - europepmc.org
Background The mechanisms driving alopecia areata (AA) are still unclear, hindering
development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides …

Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.

Y Renert‐Yuval, AB Pavel, E Del Duca, P Facheris… - Allergy, 2023 - search.ebscohost.com
Background: The mechanisms driving alopecia areata (AA) are still unclear, hindering
development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides …